Moreover, a comprehensive study extended this framework to sepsis, demonstrating that the early identification of immune subphenotypes using routinely available biomarkers (e.g., CRP levels, IL-6 levels, and lymphocyte count) could guide more precise immunomodulatory therapy. The gene discussed is IL6; the disease is Sepsis.